Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Virus And Vector Equipment Supplied In Europe
4 equipment items found
Manufactured by:SpliceBio based inBarcelona, SPAIN
SpliceBio specializes in addressing the challenges of gene therapy by leveraging engineered split inteins. Traditional adeno-associated virus (AAV) vectors are limited by size, restricting their ability to package only small genes, thus leaving many monogenic diseases without effective treatment solutions. The company has focused on the innovative application of ...
Manufactured by:Navigo Proteins GmbH based inHalle, GERMANY
In conventional biologics production, sequential multi-step downstream chromatography procedures impact, more than any other factor, overall manufacturing costs, process development and manufacturing timelines. Additionally, they pose a continuing manufacturing risk and require a different downstream process (DSP) for each new biologic. Navigo Proteins’ Precision Capturing® technology ...
Manufactured by:ProBioGen AG based inBerlin, GERMANY
ProBioGen recognized the need to overcome the limits of existing virus and viral vector production. Therefore, we created well defined, permanent cell lines for scalable and flexible virus production systems. All our proprietary cell lines are characterized by excellent productivity, safety, and stability. They are used in the industrial ...
Manufactured by:ViciniVax BV based inGroningen, NETHERLANDS
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first clinical trial, which has been started in ...